The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate
COPD is defined by chronic respiratory symptoms and the presence of fixed airflow limitation in response to smoking or particulate exposure. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy classifies patients with COPD and makes pharmacotherapeutic recommendations for their treatment according to a combined assessment approach that encompasses exacerbation risk and symptom burden. 1 Bronchodilators are an important therapeutic option in the management of symptoms in patients with stable COPD. Patients may benefit from a combination of two classes of bronchodilators, longacting muscarinic antagonists (LAMAs) and longacting b 2 -agonists (LABAs), which have different mechanisms of action. 2, 3 Glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) is a LAMA/LABA fixed-dose combination of GFF 18/9.6 mg (equivalent to glycopyrronium/formoterol fumarate dihydrate 14.4/10 mg) delivered by MDI using a novel co-suspension delivery technology. Findings from two pivotal phase III studies (PINNACLE-1 and PINNACLE-2) demonstrated the benefits of GFF MDI in patients with COPD with moderate to very severe chronic airflow limitation, compared with the individual monocomponent MDIs, a placebo MDI, and open-label tiotropium (PINNACLE-1 only). 4 Eligibility criteria for many [5] [6] [7] [8] [9] [10] but not all [11] [12] [13] [14] randomized controlled trials of LAMA/LABA combinations prespecified the inclusion of a threshold limit of COPD symptoms. The PINNACLE studies included a cross-section of patients with a broad range of COPD symptoms, 4 providing an opportunity to test the hypothesis that greater baseline symptom burden influences outcome responses to dual bronchodilator therapy.
We report findings from the post hoc analyses of pooled data from PINNACLE-1 and PINNACLE-2, evaluating the relationship between GFF MDI-associated improvements in lung function, health status, rescue medication use, and exacerbations and baseline symptom burden, as quantified with the COPD Assessment Test (CAT). This represents the first study of bronchodilator therapy in COPD to stratify measures of lung function and patient outcome results by baseline symptom burden.
Methods

Study Designs, Patients, and Treatment
Full details of the designs, treatments, eligibility criteria, end points, and statistical methods for the studies included in this analysis have been reported previously. 4 In brief, PINNACLE-1 and PINNACLE-2 were two phase III multicenter randomized double-blind parallelgroup placebo-controlled trials. They included adults (40-80 years of age) with moderate to very severe COPD who were current or ex-smokers (history of $ 10 pack-years). Moderate to very severe COPD was defined as an FEV 1 /forced vital capacity ratio < 0.7, and an FEV 1 < 80%. FEV 1 During the screening period, dyspnea and burden of disease were assessed using the Modified Medical Research Council (mMRC) dyspnea scale 15 and CAT, 16 respectively. Importantly, there was no requirement for enrolled patients to be symptomatic. The CAT is used to assess health status in COPD, with overall scores ranging from 0 to 40, and higher scores representing poorer health status. In each study, patients were randomized to 24 weeks of GFF MDI 18/9.6 mg, glycopyrrolate (GP) MDI 18 mg, formoterol fumarate (FF) MDI 9.6 mg (all administered as two actuations twice daily), or placebo MDI. PINNACLE-1 also included a cohort of patients randomized to open-label tiotropium (one capsule inhaled once daily) as an active control group. Patients were permitted to use albuterol as rescue medication on an as-needed basis.
Assessments
To characterize reversibility during screening, postbronchodilator pulmonary function tests were performed 30 min after administration of four puffs of albuterol (90 mg per actuation). The primary efficacy end point in both studies was change from baseline in the morning predose trough FEV 1 definition varied according to regional or country regulatory registration requirements; for the US approach, it was assessed at week 24, whereas for other regions, it was assessed over 24 weeks. Secondary end points included peak change from baseline in FEV 1 within 2 hours postdose, change from baseline in the St. George's Respiratory Questionnaire (SGRQ) total score, and change from baseline in average daily rescue use of albuterol over 24 weeks. COPD exacerbations were captured in both studies as additional end points, as the individual studies were not powered for this assessment. A history of COPD exacerbations was not a study inclusion requirement.
Spirometry was performed according to American Thoracic Society criteria. 17 The SGRQ 18 provided data on patients' health-related quality of life. Study medication compliance and rescue medication (albuterol) use was recorded daily in a patient electronic diary. Both studies used standard definitions of exacerbations 4 ; a moderate exacerbation was defined as an exacerbation that required treatment with systemic steroids or antibiotics, or both, and did not result in hospitalization or death. A severe exacerbation was defined as an exacerbation that resulted in hospitalization or death.
Statistical Analysis
These post hoc analyses of pooled data were conducted using the intent-to-treat (ITT) population and subgroups of the population stratified by CAT score at baseline ($ 10, $ 15, and $ 20). The pooled ITT population was defined as all patients who were randomized and received at least one dose of study drug in PINNACLE-1 or PINNACLE-2. All efficacy end points were evaluated relative to predose baselines obtained at or prior to day 1.
Spirometric, health status, and rescue medication use outcomes were analyzed using a repeated-measures linear model that included bronchodilator (albuterol) reversibility as a continuous covariate and study (PINNACLE-1 or PINNACLE-2), treatment, visit, treatment by visit interaction, baseline smoking status, and baseline inhaled corticosteroid (ICS) use as categorical covariates. In addition, baseline values for FEV 1 , SGRQ total score, and mean daily number of puffs of rescue medication (albuterol) were used as continuous covariates in the analyses of spirometry, health status, and rescue medication use, respectively. The variance-covariance matrix for the repeated measures was fit as unstructured. Logistic regression analysis was performed for treatment differences in the proportion of patients achieving the minimum clinically important difference (MCID) in SGRQ total score of at least -4 units at week 24, which included baseline SGRQ total score, bronchodilator reversibility, baseline smoking status, baseline ICS use, and study as covariates. Two-sided P values and point estimates were produced for each treatment difference/ratio. P values < .05 are reported as statistically significant without additional control for type I error. Additional details on the statistical analysis of COPD exacerbations is provided in the Supplementary Methods section of e-Appendix 1.
Results
Study Population
Patient disposition and details of patient demographic and clinical characteristics at baseline have been reported previously for the study-specific 4 and pooled data set 19 ; therefore, only a brief overview will be provided here. Of the 3,699 patients included in the analysis of pooled data from PINNACLE-1 and PINNACLE-2, 3,002 (81.2%) completed 24 weeks of treatment. Patient demographics and baseline clinical characteristics for all subjects and those in different baseline CAT categories are shown in Table 1 . The distribution of patients with baseline CAT scores was < 10 in 12% (n ¼ 455), $ 10 in 87% (n ¼ 3,227), $ 15 in 69% (n ¼ 2,544), and $ 20 in 44% (n ¼ 1,617) of patients; baseline CAT score data were missing for 17 patients (< 1%). The relationship between CAT score and mMRC grade is shown in Figure 1 . Patients with an mMRC grade of 2 had an average CAT score of 20. The correlation between CAT and SGRQ scores was consistent with previous reports (r ¼ 0.706; R 2 ¼ 0.498) (e- Fig 1) . 20 
Lung Function Outcomes
The patient baseline CAT scores observed in the GFF MDI group appeared to have no effect on the magnitude of improvement in the morning predose trough FEV 1 at week 24 compared with the GP MDI and FF MDI groups (least squares mean [LSM] differences, 55-58 mL and 56-61 mL, respectively) or improvement from baseline with GFF MDI vs placebo MDI (LSM differences, 109-126 mL) (Fig 2A) . The magnitude of improvement from baseline in peak FEV 1 at week 24 with GFF MDI vs the monocomponent MDIs was similar across the baseline CAT score subgroups (GP MDI: LSM differences, 130-137 mL; FF MDI: LSM differences, 87-90 mL) (Fig 2B) . Similarly, no impact of baseline CAT score was seen on the magnitude of improvement from baseline in peak FEV 1 at week 24 for GFF MDI compared with placebo MDI (LSM differences, 271-280 mL). Similar results were observed for both end points when effects over the entire 24-week treatment period were considered (e- Tables 1, 2 ).
Health-Related Quality of Life Outcomes
For treatment differences in change from baseline in the SGRQ total score at week 24, the magnitude of improvement with GFF MDI vs monocomponent MDIs and placebo MDI exhibited a trend for increasing with higher CAT scores (Fig 3A) . The difference in the proportion of patients achieving the MCID for SGRQ total score at week 24 between GFF MDI and monocomponent MDIs and placebo MDI was numerically greatest in patients with baseline CAT scores $ 20 ( Fig 3B) . Similar results were observed from the analysis of SGRQ total score over 24 weeks chestjournal.org Rescue Medication Use
Treatment differences in change from baseline in rescue medication use over 24 weeks showed a similar magnitude of reduction with GFF MDI vs GP MDI, irrespective of baseline CAT score, whereas numerically greater reductions with GFF MDI vs FF MDI and placebo MDI were observed as a function of increasing CAT scores (e- Table 6 ).
Moderate or Severe COPD Exacerbations
The rates of exacerbations increased as the baseline CAT score increased. Treatment incidence rate ratios for GFF MDI vs GP MDI, FF MDI, and placebo MDI imply that GFF MDI reduces the rate of moderate or severe exacerbations, with increasing benefit demonstrated as a function of baseline CAT scores (Table 2 ). Hazard ratios demonstrated that GFF MDI is associated with a longer time to, and lower risk of, first moderate or severe exacerbations compared with GP MDI, FF MDI, and placebo MDI (Fig 4) . The magnitude of these GFFrelated MDI improvements vs each of the monocomponent MDIs and the placebo MDI were also potentially related to increasing baseline CAT scores.
Discussion
COPD is a heterogeneous disorder in which assessment of lung function impairment is mandatory for diagnosis and overall risk assessment. Although studies have found a relationship between decrements in FEV 1 and the severity of pathologic changes in the small airways, 21 lung function impairment is not reflected in disease severity as defined by GOLD 2017. 1 Hence, pharmacotherapeutic strategies now recommend therapeutic decisions based on symptomatic impairment and exacerbation risk rather than lung function. chestjournal.org the MCID for the instruments used to measure these outcomes, although modest improvement in proportional analyses have been noted. [23] [24] [25] Similar variability has been observed when investigative groups have examined health status. [23] [24] [25] Our data set allowed us to test the hypothesis that a greater baseline symptom burden identifies a patient population more likely to experience clinical improvements with dualbronchodilator therapy compared with placebo and the individual monocomponents.
In the pooled PINNACLE-1 and PINNACLE-2 data, we demonstrated that for patients with a baseline mMRC grade of 2, the mean baseline CAT score was 20. This is consistent with the findings from other studies showing that an mMRC grade of 2 generally equates to an average range of CAT score of 16 to 20. [26] [27] [28] In contrast, GOLD uses a CAT score of 10 or an mMRC score of 2 to establish a boundary between GOLD A/C (fewer symptoms) and GOLD B/D (more symptoms) patient subgroups. 1 Although GOLD does not state that the CAT and mMRC scores are related and recognizes that these patient-reported outcomes have different purposes, additional studies to generate data and a framework of reference are needed to confirm whether the CAT score of 10 is an appropriate cutoff point.
Overall, GFF MDI improved SGRQ total score by more than the monocomponent MDIs and placebo MDI in each of the patient subgroups (CAT $ 10, $ 15, and $ 20). Importantly, the observed magnitude of GFF MDI 18/9.6 µg vs FF MDI 9.6 µg GFF MDI 18/9.6 µg vs placebo MDI GFF MDI 18/9.6 µg vs GP MDI 18 µg GFF MDI 18/9.6 µg vs FF MDI 9.6 µg GFF MDI 18/9.6 µg vs placebo MDI Figure 3 -Relationship between baseline CAT score and (A) the magnitude of improvement in change from baseline in the SGRQ total score at week 24 and (B) the proportion of patients achieving the MCID for SGRQ total score at week 24 for GFF MDI vs comparator (95% CI). MCID was defined as a four-unit improvement in SGRQ total score. *P < .05; † P < .01. MCID ¼ minimum clinically important difference; SGRQ ¼ St. George's Respiratory Questionnaire. See Figure 1 and 2 legends for expansion of other abbreviations. improvement in SGRQ total scores achieved with GFF MDI vs monocomponent MDIs and the placebo MDI was noticeably greater in those with a baseline CAT score $ 20. The proportion of individuals who achieved the MCID for SGRQ total score with GFF MDI vs monocomponent MDIs and a placebo MDI was also greatest in patients with a baseline CAT score $ 20. Previous studies have varied in the requirement to include patients exhibiting a baseline level of symptoms. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These studies have generally demonstrated that the combination of a LAMA/LABA improves health status to a greater extent than does placebo, although the results compared with individual monocomponents have been inconsistent. 24, 25 Our data suggest that this could relate to the broader range of health status reported at baseline, which appeared to be independent of the magnitude of change in FEV 1 .
Importantly, we documented similar improvement in other clinical parameters as a function of baseline symptom burden. Reductions in rescue medication use with GFF MDIs vs FF MDIs and a placebo MDI trended toward being greater in patients with higher baseline CAT scores. As anticipated, the rates of exacerbations were higher in patients with greater baseline CAT scores. 27 The magnitude of observed improvements in moderate or severe COPD exacerbations with GFF MDI vs each of the monocomponent MDIs and placebo MDI was numerically greater with increasing baseline CAT score. In contrast, improvements in lung function observed during treatment with twice-daily GFF MDIs vs monocomponent MDIs and a placebo MDI were achieved regardless of patients' CAT-measured COPD symptom burden at baseline.
In the recently updated GOLD combined COPD assessment, spirometric grades were separated from the ABCD assessment tool. 1 The results of the analysis described here support the notion of considering lung function separately from patient-reported outcomes, as the improvements observed for lung function were consistent across the scale of baseline CAT scores, whereas seemingly larger improvements in SGRQ score and exacerbation rate were observed in patients with greater symptom burden.
Several limitations apply to our findings due to the post hoc nature of the analyses. Neither study protocol included prespecified criteria to ensure balanced recruitment within CAT score-defined symptom burden subgroups. As a result, the number of patients with a CAT score < 10 was not large enough for a meaningful analysis of this subgroup. The studies were not prospectively powered to detect differences in all the reported outcome measures across the spectrum of COPD symptom burden. In particular, the studies were not designed to evaluate exacerbations, that is, they were not powered for an analysis of exacerbations, as a history of COPD exacerbations was not a study entry requirement, and the modified Anthonisen criteria defining an exacerbation were not captured in the patients' symptom diaries. There was the possibility of a ceiling effect in patients at the lower end of the symptom burden continuum. This data set did not allow us to assess if the addition of an antiinflammatory drug to the treatment regimens, such as an ICS, provides additional benefit in these patients; further studies in this regard are needed. Finally, most of the patients were from the United States (ie, a high-income country), and socioeconomic status may impact the improvements in SGRQ scores observed following treatment with bronchodilators or placebo in clinical trials. 29 
Conclusions
These findings support assessment of lung function across the spectrum of disease severity; however, assessment of symptomatic benefit requires standardization and should preferentially include those subjects most likely to derive this benefit based on an elevated CAT score or mMRC dyspnea score during the screening phase. As we move toward precision medicine, 30 careful assessment of baseline symptoms may be key in determining the most appropriate therapeutic strategy, such as initiating LAMA/LABA therapy in patients presenting with higher symptomatic burden. Data shown are for patients with evaluable data for each end point. *P < .05; † P < .01. HR ¼ hazard ratio. See Figure 1 and 2 legends for expansion of other abbreviations. Therapeutics Inc, Sunovian, and Theravance.
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